Literature DB >> 21876631

Trend in gastric cancer: 35 years of surgical experience in Japan.

Keishi Yamashita1, Shinichi Sakuramoto, Masayuki Nemoto, Tomotaka Shibata, Hiroaki Mieno, Natsuya Katada, Shiroh Kikuchi, Masahiko Watanabe.   

Abstract

AIM: To investigate the trend in gastric cancer surgery in the context of rapid therapeutic advancement in Japan and East Asia.
METHODS: A retrospective analysis was performed on 4163 patients who underwent gastric resection for gastric cancer with histological confirmation between 1971 and 2007 at the surgical unit in Kitasato University Hospital, to determine the trend in gastric cancer requiring surgery.
RESULTS: Gastric cancer requiring surgical resection increased in our hospital, but the incidence adjusted for population was constant during the observed period. Interestingly, the ratio of diffuse type/intestinal type gastric cancer was unexpectedly unchanged, and that of advanced/early gastric cancer (EGC) was, however, markedly reduced, while the actual incidence of potentially curative advanced gastric cancer tended to decrease. The incidence of EGC requiring surgery tended to increase as a whole, which is consistent with increased prevalence of endoscopic surveillance. As a result, overall survival and mortality of gastric cancer requiring gastric resection has recently markedly improved.
CONCLUSION: In Japan, planned interventions may improve surgical gastric cancer mortality, but an unexpected trend of persistent existence of intestinal type cancer suggests the need for more robust medical intervention.

Entities:  

Keywords:  Age factors; Clinical classification; Disease progression; Gastric cancer; Histology; Prognosis

Mesh:

Year:  2011        PMID: 21876631      PMCID: PMC3160565          DOI: 10.3748/wjg.v17.i29.3390

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  20 in total

1.  Usefulness of endoscopic aspiration mucosectomy as compared with strip biopsy for the treatment of gastric mucosal cancer.

Authors:  S Tanabe; W Koizumi; M Kokutou; H Imaizumi; K Ishii; M Kida; Y Yokoyama; M Ohida; K Saigenji; H Shimao; H Mitomi
Journal:  Gastrointest Endosc       Date:  1999-12       Impact factor: 9.427

2.  Cancer of the gastric stump following distal gastrectomy for cancer.

Authors:  M Ohashi; H Katai; T Fukagawa; T Gotoda; T Sano; M Sasako
Journal:  Br J Surg       Date:  2007-01       Impact factor: 6.939

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

4.  Gastric leptin and Helicobacter pylori infection.

Authors:  T Azuma; H Suto; Y Ito; M Ohtani; M Dojo; M Kuriyama; T Kato
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

5.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Authors:  Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

6.  Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial.

Authors:  Kazutoshi Fukase; Mototsugu Kato; Shogo Kikuchi; Kazuhiko Inoue; Naomi Uemura; Shiro Okamoto; Shuichi Terao; Kenji Amagai; Shunji Hayashi; Masahiro Asaka
Journal:  Lancet       Date:  2008-08-02       Impact factor: 79.321

7.  Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.

Authors:  Narikazu Boku; Seiichiro Yamamoto; Haruhiko Fukuda; Kuniaki Shirao; Toshihiko Doi; Akira Sawaki; Wasaburo Koizumi; Hiroshi Saito; Kensei Yamaguchi; Hiroya Takiuchi; Junichiro Nasu; Atsushi Ohtsu
Journal:  Lancet Oncol       Date:  2009-10-07       Impact factor: 41.316

8.  The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease.

Authors:  J J Vicari; R M Peek; G W Falk; J R Goldblum; K A Easley; J Schnell; G I Perez-Perez; S A Halter; T W Rice; M J Blaser; J E Richter
Journal:  Gastroenterology       Date:  1998-07       Impact factor: 22.682

Review 9.  Epidemiology and clinical characteristics of GERD in the Japanese population.

Authors:  Yasuhiro Fujiwara; Tetsuo Arakawa
Journal:  J Gastroenterol       Date:  2009-04-14       Impact factor: 7.527

10.  Time trend analysis of gastric cancer incidence in Japan by histological types, 1975-1989.

Authors:  S Kaneko; T Yoshimura
Journal:  Br J Cancer       Date:  2001-02-02       Impact factor: 7.640

View more
  35 in total

Review 1.  Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction.

Authors:  Kei Hosoda; Keishi Yamashita; Natusya Katada; Masahiko Watanabe
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-08-01

2.  Gastric precancerous lesions are associated with gene variants in Helicobacter pylori-susceptible ethnic Malays.

Authors:  Sathiya Maran; Yeong Yeh Lee; Shuhua Xu; Nur-Shafawati Rajab; Norhazrini Hasan; Syed Hassan Syed Abdul Aziz; Noorizan Abdul Majid; Bin Alwi Zilfalil
Journal:  World J Gastroenterol       Date:  2013-06-21       Impact factor: 5.742

3.  Long-term prognostic outcome of cT1 gastric cancer patients who underwent laparoscopic gastrectomy after 5-year follow-up.

Authors:  Keishi Yamashita; Kei Hosoda; Hiromitsu Moriya; Hiroaki Mieno; Natsuya Katada; Masahiko Watanabe
Journal:  Langenbecks Arch Surg       Date:  2016-03-19       Impact factor: 3.445

4.  Robust vascular invasion concurrent with intense EGFR immunostaining can predict recurrence in patients with stage IB node-negative gastric cancer.

Authors:  Ippeita Araki; Marie Washio; Keishi Yamashita; Kei Hosoda; Akira Ema; Hiroaki Mieno; Hiromitsu Moriya; Natsuya Katada; Shiro Kikuchi; Masahiko Watanabe
Journal:  Surg Today       Date:  2017-12-18       Impact factor: 2.549

5.  DNA diagnosis of peritoneal fluid cytology test by CDO1 promoter DNA hypermethylation in gastric cancer.

Authors:  Hideki Ushiku; Keishi Yamashita; Akira Ema; Naoko Minatani; Mariko Kikuchi; Ken Kojo; Keigo Yokoi; Toshimichi Tanaka; Nobuyuki Nishizawa; Satoru Ishii; Kei Hosoda; Hiromitsu Moriya; Hiroaki Mieno; Natsuya Katada; Shiro Kikuchi; Hiroshi Katoh; Masahiko Watanabe
Journal:  Gastric Cancer       Date:  2017-02-27       Impact factor: 7.370

6.  Molecular dysexpression in gastric cancer revealed by integrated analysis of transcriptome data.

Authors:  Xiaomei Li; Weiwei Dong; Xueling Qu; Huixia Zhao; Shuo Wang; Yixin Hao; Qiuwen Li; Jianhua Zhu; Min Ye; Wenhua Xiao
Journal:  Oncol Lett       Date:  2017-03-03       Impact factor: 2.967

Review 7.  Targeting receptor tyrosine kinases in gastric cancer.

Authors:  Asahiro Morishita; Jian Gong; Tsutomu Masaki
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

8.  Prognoses of advanced esophago-gastric junction cancer may be modified by thoracotomy and splenectomy.

Authors:  Kei Hosoda; Keishi Yamashita; Harukazu Tsuruta; Hiromitsu Moriya; Hiroaki Mieno; Akira Ema; Marie Washio; Masahiko Watanabe
Journal:  Oncol Lett       Date:  2017-11-17       Impact factor: 2.967

9.  Galectin-8 is associated with recurrence and survival of patients with non-metastatic gastric cancer after surgery.

Authors:  Songyang Wu; Hao Liu; Heng Zhang; Chao Lin; Ruochen Li; Yifan Cao; Hongyong He; He Li; Zhenbin Shen; Jing Qin; Jiejie Xu
Journal:  Tumour Biol       Date:  2016-07-21

10.  Laparoscopic versus open distal gastrectomy for early gastric cancer in Japan: long-term clinical outcomes of a randomized clinical trial.

Authors:  Keishi Yamashita; Shinichi Sakuramoto; Shiro Kikuchi; Nobue Futawatari; Natsuya Katada; Kei Hosoda; Hiromitsu Moriya; Hiroaki Mieno; Masahiko Watanabe
Journal:  Surg Today       Date:  2015-07-30       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.